Daré Bioscience, Inc. completed the second closing of its previously announced unregistered securities offering on March 6, 2026, as disclosed in this Form 8-K filing dated March 9, 2026. This event falls under Item 3.02, indicating an unregistered sale of equity securities that may impact the company's capitalization and shareholder base.